Eli Lilly and CompanyvsMineralys Therapeutics

LLY and MLYS stock compared: price, dividend, valuation and results, from SEC filings.

LLY

Eli Lilly and Company

$1,347.11

Value $1.27T

-0.30%
LLY's page

MLYS

Mineralys Therapeutics, Inc.

$13.66

Value $1.2B

-3.53%
MLYS's page

Eli Lilly and Company (LLY) has a market value of $1.27T and Mineralys Therapeutics (MLYS) $1.2B. Over the last year, with dividends, LLY moved +29.1% and MLYS -67.6%. Dividend yield: LLY 0.47%, MLYS none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    LLY$1.27T

    MLYS$1.2B

    LLY is 1,051 times MLYS

  • Revenue, 12 months

    LLY$86.5B

    MLYS–

  • Net income, 12 months

    LLY$27.6B

    MLYS-$370M

  • Operating margin

    LLY–

    MLYS–

  • ROIC

    LLY35.5%

    MLYS-20.8%

    56.3 points apart

  • P/E

    LLY46.1

    MLYS–

  • Dividend yield

    LLY0.5%

    MLYS0.0%

    0.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

LLY+129.9%

MLYS+112.4%

200400600202420252026
Returns by period
PeriodLLYWith dividendsMLYSWith dividends
1 year since November 19, 2025+29.1%Price +28.3%-67.6%Price -67.6%
3 years since November 20, 2023+130.0%+32.0% a yearPrice +125.4%+112.4%+28.6% a yearPrice +112.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

LLYEli Lilly and CompanyMLYSMineralys Therapeutics

Valuation

LLYMLYS
Valuation
Price$1,347.11$13.66
Market value$1.27T$1.2B
Enterprise value (EV)$1.32T$585M
P/E46.1–
P/E, 5-year median49.9–
P/B31.62.4
EV/EBIT37.8–
Free cash flow yield1.6%–

Results and growth

LLYMLYS
Results and growth
Revenue, 12 months$86.5B–
Net income, 12 months$27.6B-$370M
Free cash flow, 12 months$19.7B-$153M
Earnings per share, 12 months$30.81-$4.31
Revenue growth, year on year44.7%–
Revenue growth a year, past+21.6%over 5 years–
EPS growth a year, past+27.6%over 5 years–

Margins and returns on capital

LLYMLYS
Margins and returns on capital
Gross margin83.6%–
Operating margin––
Net margin31.9%–
ROIC35.5%-20.8%
ROE88.6%-63.4%

Balance sheet

LLYMLYS
Balance sheet
Cash$4.9B$625M
Total debt$49.5B$100.0K
Net debt / EBITDA1.2–
Interest cover38.9×–

Dividends and buybacks

LLYMLYS
Dividends and buybacks
Dividend yield0.5%–
Dividend per share, 12 months$6.34–
Dividend growth a year, past+15.2%over 5 years–
Buyback yield0.3%–
Shareholder yield0.8%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: LLY or MLYS

Didn't find what you were looking for?

Ask us
Which is bigger, Eli Lilly and Company or Mineralys Therapeutics?

By market value, Eli Lilly and Company ($1.27T) is about 1,050.5 times Mineralys Therapeutics ($1.2B), at today's prices.

How did LLY and MLYS stock do over the last 3 years?

Since November 20, 2023, LLY's price moved +125.4% and MLYS's +112.4%. With dividends: LLY +130.0% (+32.0% a year), MLYS +112.4% (+28.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, LLY or MLYS?

The dividend yield at today's price is 0.47% for Eli Lilly and Company and none for Mineralys Therapeutics. Over the last twelve months they paid $6.34 and – per share.

Which is the better investment, Eli Lilly and Company or Mineralys Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.